Phase
Condition
N/ATreatment
pembrolizumab plus axitinib
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients aged >18y
Cytological or Histologically confirmed diagnosis of clear cell or non-clear cellRCC
Histologically or radiologically confirmed diagnosis of metastatic disease
First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinibor pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plusaxitinib or atezolizumab plus bevacizumab
Exclusion
Exclusion Criteria:
Patients without histologically confirmed diagnosis of RCC
Patients without histologically or radiologically confirmed metastatic disease
Patients treated with immuno-combinations not included in the list reported in theInclusion Criteria Section
Study Design
Connect with a study center
Ospedale di Macerata, UOC Oncologia
Macerata, 62100
ItalyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.